Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06607120
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-26
Brief Title:
Prognosis Stratification for Advanced HCC Receiving TACE with PD-1PD-L1 Inhibitors and Molecular Target Therapies
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Personalized Model of Prognosis Stratification for Patients with Advanced HCC Receiving TACE Combined with PD-1PD-L1 Inhibitors Plus Molecular Target Therapies
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma HCC receiving transarterial chemoembolization TACE in combination with immune checkpoint inhibitors ICIs and molecular target therapies
Detailed Description:
In patients with advanced-stage hepatocellular carcinoma HCC previous studies showed that transarterial chemoembolization TACE in combination with immune checkpoint inhibitors ICIs and molecular target therapies exhibited better efficacy PFS and OS as compared to the ICIs and molecular target therapies However there is a lack of effective tools to select those who will benefit the most from that combination therapy The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage HCC who receive TACE and immune checkpoint ICIs plus molecular target therapies including VEGF-TKI bevacizumab This real-world study may provide further information on treatment selection for clinical practice and trials
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None